ALLE
39
-2
ORLY
64
-2
BLK
55
-2
HCP
62
2
ECL
62
2
AMGN
33
2
L
65
-3
TXT
55
2
MRK
35
-5
LRCX
46
4
FIS
46
-2
UNP
56
-3
RL
82
3
BXP
55
-4
ORCL
58
3
CMS
61
-3
EW
41
-5
LMT
32
2
AVY
57
2
MTB
65
-3
ALLE
39
-2
ORLY
64
-2
BLK
55
-2
HCP
62
2
ECL
62
2
AMGN
33
2
L
65
-3
TXT
55
2
MRK
35
-5
LRCX
46
4
FIS
46
-2
UNP
56
-3
RL
82
3
BXP
55
-4
ORCL
58
3
CMS
61
-3
EW
41
-5
LMT
32
2
AVY
57
2
MTB
65
-3
Financhill
Back

Addex Therapeutics 10K Form

Sell
29

ADXN
Addex Therapeutics

Last Price:
8.95
Seasonality Move:
54.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ADXN News And Ratings

See the #1 stock for the next 7 days that we like better than ADXN

ADXN Financial Statistics

Sales & Book Value

Annual Sales: $1.8M
Cash Flow: $-713.3K
Price / Cash Flow: 0
Annual Sales: $12.30
Price / Book: 0.71

Profitability

EPS (TTM): -0.34150
Net Income (TTM): $5.72M
Gross Margin: $2.55M
Return on Equity: 91.08%
Return on Assets: 62.62%

Addex Therapeutics Earnings Forecast

Key Addex Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for ADXN is 91.70%.
  • The Selling, General & Administrative Expenses for ADXN have been equal to 446.69% of Gross Profit Margin.
  • The Research & Development expenses have been 170.40% of Revenue.
  • The Interest Expense is -0.20% of Operating Income.
  • The Net Earning history of ADXN is -654.47% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 13 years.

Addex Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ADXN
Website: addextherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.59
Quick Ratio: 4.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ADXN Technical Analysis vs Fundamental Analysis

Sell
29
Addex Therapeutics (ADXN) is a Sell

Is Addex Therapeutics a Buy or a Sell?